Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

27.13 +27.13 (+1043361.54%)
Streaming Delayed Price Updated: 9:36 AM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for uniQure ↗
 
Via Benzinga
News headline image
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
News headline image
uniQure to Participate in Multiple Upcoming Industry Conferences in March
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Stock Trying To Close In On Key Technical Measure ↗
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score. 
Via Investor's Business Daily
News headline image
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market... 
Via Benzinga
News headline image
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
From uniQure Inc.
Via GlobeNewswire
News headline image
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline ↗
UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). 
Via Benzinga
News headline image
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
From uniQure Inc.
Via GlobeNewswire
News headline image
3 Growth Stocks That Could Rocket Higher in 2023 ↗
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
News headline image
Newly Approved Drugs In US Command Over $200,000 On An Average ↗
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. 
Via Benzinga
News headline image
Have A Look At William Blair's Top Biotech Picks For 2023 ↗
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
News headline image
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B 
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
From uniQure Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
News headline image
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
News headline image
Why Shares of uniQure Rose 14.61% on Wednesday ↗
A big approval for a gene therapy sent the biotech's stock higher. 
Via The Motley Fool
News headline image
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath ↗
And shares of its developer are on a warpath this week. 
Via Investor's Business Daily
News headline image
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗
 
Via Benzinga
News headline image
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure: Q3 Earnings Insights ↗
uniQure (NASDAQ:QURE) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings uniQure beat estimated earnings by... 
Via Benzinga
News headline image
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration Capabilities 
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure to Participate in Upcoming Industry Conferences in October
From uniQure Inc.
Via GlobeNewswire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.